News Summary
Researchers at the University of Arizona College of Medicine – Tucson, led by Dr. Michael D. L. Johnson, have developed a new drug leveraging copper’s antimicrobial properties. This breakthrough offers hope in combating antibiotic-resistant bacteria, targeting strains like MRSA and Streptococcus pneumoniae. The drug employs a unique ‘Trojan horse’ mechanism to deliver a toxic dose of copper into bacterial cells, showcasing the university’s commitment to advancing public health and scientific discovery.
Phoenix, AZ — The University of Arizona College of Medicine – Tucson has announced a significant advancement in the fight against antibiotic-resistant bacteria, with researchers developing a new drug that harnesses the antimicrobial properties of copper. This breakthrough, led by Dr. Michael D. L. Johnson, an associate professor of immunobiology, represents a promising new avenue in addressing critical public health challenges posed by drug-resistant infections. The innovation underscores the commitment of Arizona’s higher education institutions to academic rigor and scientific discovery that yields tangible benefits for society.
This development is particularly relevant in the broader context of Arizona AZ higher education, where research initiatives often translate into advancements with significant community and economic impact. The work at the University of Arizona College of Medicine – Tucson exemplifies the institution’s dedication to fostering a culture of innovation and problem-solving. By exploring novel approaches to persistent medical threats, the university continues to solidify its role as a leader in biomedical research and a vital contributor to the state’s intellectual and economic landscape.
Leveraging Copper’s Ancient Power
The core of this new drug involves the strategic use of copper, a metal with a long history of antimicrobial applications dating back thousands of years. Early civilizations utilized copper for various purposes, including storing food to prevent spoilage, and more recently, copper surfaces have been recognized for their ability to reduce hospital-acquired infections. Dr. Johnson’s research builds upon this historical understanding, seeking to weaponize copper effectively against modern bacterial threats. The inherent toxicity of copper to bacteria makes it an ideal candidate for developing next-generation antibiotics.
The “Trojan Horse” Mechanism
The innovative drug employs a compound named BMDC (N-benzyl-N-methyldithiocarbamate), which acts as a “Trojan horse” to deliver a lethal dose of copper directly into bacterial cells. Bacteria actively scavenge for essential nutrients like iron from their environment. The BMDC compound is designed to mimic these iron-carrying molecules. When bacteria absorb what they perceive as iron, they inadvertently take in the copper-laden BMDC, leading to their intoxication and death. This clever deceptive mechanism aims to overcome bacterial defenses and resistance strategies.
The mechanism of copper’s bactericidal activity is multifaceted. It primarily involves the generation of reactive oxygen species (ROS), which cause irreversible damage to bacterial membranes. Copper ions can also lead to RNA degradation and disrupt fungal membranes. The Johnson Lab’s research specifically investigates how the body naturally uses copper to fight pathogens, aiming to enhance this process for therapeutic purposes.
Targeting Critical Antibiotic-Resistant Strains
This copper-based drug demonstrates significant efficacy against some of the most challenging antibiotic-resistant pathogens. Notably, it has shown promise against MRSA (methicillin-resistant Staphylococcus aureus) and Streptococcus pneumoniae. MRSA is designated as a serious threat by the Centers for Disease Control and Prevention (CDC) and a high-priority pathogen by the World Health Organization (WHO) due to its resistance to common treatments and its role in both community and hospital-acquired infections. The drug also targets Staphylococcus epidermidis, a related bacterium that can cause hospital infections, particularly around medical plastics.
Laboratory findings indicate that this technology can eradicate over 99% of both MRSA and Streptococcus pneumoniae within a four-hour period. Furthermore, studies in animal models have shown its effectiveness as an inhalant against lethal doses of Streptococcus pneumoniae pneumonia after only a single dose, demonstrating good tolerability.
Strategic Funding and Future Prospects
The research at the University of Arizona College of Medicine – Tucson has received substantial support, including a $1.9 million grant from the National Institutes of Health (NIH). This R35 grant is specifically awarded to scientists with exceptional research records and the potential for major contributions to their fields. This marks the second NIH grant Dr. Johnson has secured for his work on copper’s impact on bacteria. Additional funding has been provided by Tech Launch Arizona (TLA) through its Asset Development Program, which assists in moving impactful innovations toward commercialization and real-world application. The intellectual property related to this core technology and its derivatives is protected by a patent.
The development of this drug represents a crucial step in building a robust toolkit against bacterial infections, especially given bacteria’s inherent ability to evolve drug resistance. The unique mechanism, requiring bacteria to mutate multiple pathways simultaneously to resist the copper intoxication without compromising their survival, suggests a potentially lower likelihood of resistance development compared to conventional antibiotics.
Fostering Future Leaders in Science
The University of Arizona is deeply committed to nurturing the next generation of scientific leaders. Through programs such as the Medical Student Research Program (MSRP) at the College of Medicine, students are provided with invaluable opportunities to engage in hands-on research and collaborate with faculty mentors. These experiences are designed to enrich their education beyond traditional classroom and clinical settings, fostering a deeper understanding of scientific inquiry and its real-world applications. Student involvement in cutting-edge projects like the copper-based drug research is integral to addressing significant challenges facing Arizona and the nation. The College of Medicine – Phoenix also offers lab volunteer and intern positions, allowing aspiring researchers to contribute to ongoing studies and gain practical experience.
The economic and public health implications of antibiotic resistance are substantial, with resistant pathogens costing the U.S. healthcare system billions annually and leading to millions of additional hospital days. Innovations such as the copper-based drug offer hope for reducing these burdens and improving global health outcomes, further cementing the importance of University of Arizona AZ research and Phoenix AZ college news in the national dialogue.
Key Features of the Copper-Based Drug
| Feature | Description |
|---|---|
| Lead Researcher | Dr. Michael D. L. Johnson, Associate Professor of Immunobiology |
| Drug Compound | BMDC (N-benzyl-N-methyldithiocarbamate) |
| Mechanism | “Trojan horse” mimics iron, delivers toxic copper dose to bacteria |
| Target Pathogens | MRSA, Streptococcus pneumoniae, Staphylococcus epidermidis |
| Efficacy | >99% kill rate for MRSA/S. pneumoniae in 4 hours; effective as inhalant in mouse model |
| Funding | $1.9 million NIH grant, Tech Launch Arizona Asset Development Program |
| Status | Published in mSphere (Dec 2025); patented technology; ongoing studies |
The ongoing development of this copper-based drug by the University of Arizona College of Medicine – Tucson highlights the significant contributions of Arizona AZ higher education to national and global health. This research not only offers a new weapon against antibiotic resistance but also demonstrates the profound impact of disciplined scientific inquiry and personal responsibility in tackling complex societal challenges. Readers are encouraged to stay informed on the advancements emerging from Phoenix’s vibrant college community and explore the various programs and opportunities available at its esteemed universities.
Frequently Asked Questions about the University of Arizona’s Copper-Based Drug
- Who is leading the research on the copper-based drug?
The research is led by Dr. Michael D. L. Johnson, an associate professor of immunobiology at the University of Arizona College of Medicine – Tucson.
- What is the new drug compound called and how does it work?
The new drug compound is called BMDC (N-benzyl-N-methyldithiocarbamate). It functions as a “Trojan horse” by mimicking iron, which bacteria mistakenly absorb, leading to their demise from a toxic dose of copper.
- What types of bacteria does this new drug target?
The drug is effective against challenging antibiotic-resistant pathogens, including MRSA (methicillin-resistant Staphylococcus aureus), Streptococcus pneumoniae, and Staphylococcus epidermidis.
- How effective is the copper-based drug in preliminary tests?
Laboratory tests show the technology can kill over 99% of MRSA and Streptococcus pneumoniae within four hours. It has also been effective as an inhalant against a lethal dose of Streptococcus pneumoniae pneumonia in mouse models.
- What funding has the research received?
The research has been supported by a $1.9 million grant from the National Institutes of Health (NIH) and funding from Tech Launch Arizona (TLA) through its Asset Development Program.
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE PHOENIX WRITER
The PHOENIX STAFF WRITER represents the experienced team at HEREPhoenix.com, your go-to source for actionable local news and information in Phoenix, Maricopa County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the Waste Management Phoenix Open, Cactus League Spring Training, and Arizona State Fair. Our coverage extends to key organizations like the Greater Phoenix Chamber of Commerce and Visit Phoenix, plus leading businesses in technology and healthcare that power the local economy such as Intel and Banner Health. As part of the broader HERE network, including HERETucson.com, we provide comprehensive, credible insights into Arizona's dynamic landscape.
